Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Cord Blood America, Inc. (CBAI.OB) Provides Update for Stem Cell Collection Business in China

|Includes: Cord Blood America, Inc. (CBAI)

Located in Las Vegas, Nevada, Cord Blood is the parent company of CorCell which provides umbilical cord blood stem cell preservation for expectant parents with the corporate mission to be the most respectful stem cell preservation company in the industry. Today, Cord Blood announced it has taken another step towards becoming a stronger global power.

The announcement explains that Cord Blood has joined forces with several parties to form a new company called China Stem Cells that will have Cord Blood CEO and co-founder Matthew Schissler serve as President of the new company.

As for Cord Blood’s overall progress in China, Schissler provided an update in an interview with analyst Francis Gaskins. In the interview, Schissler explains changes to the structure of the transition into the Chinese market and elaborates on changes made since the original announcement on March 31, 2010. The entire interview is available at: gaskinsco.com/cbai-10-25.mp3.

When asked what this announcement will mean to the future of Cord Blood, Schissler was quoted as saying, “This is a more cost effective, smoother process and it gives Cord Blood America a strategic footprint into the Far East.” Schissler then explained that the Chinese are storing stem cells at rates faster than the U.S. and Europe.

Currently, Cord Blood America is trading in the $0.0042 range. With the expansion into China and a strong corporate team in place, Cord Blood may evolve into a global power in the near future.

To learn more about the company, visit: cordblood-america.com or corcell.com

Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net


Disclosure: no positions